The process for registering a new drug in South Korea involves submitting a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS). It includes preclinical and clinical data, manufacturing details, and safety evaluations. The MFDS reviews the application for efficacy, safety, and quality, followed by market approval if standards are met.